Any DEA-licensed prescriber can now prescribe buprenorphine for the treatment of opioid use disorder, but only around half of U.S. pharmacies stock it because of controlled substance purchasing and dispensing requirements. To help pharmacists bring the lifesaving drug to more communities, NCPA partnered with the National Association of Boards of Pharmacy, the University of Houston College of Pharmacy, and others to create a first-of-its-kind practice guideline for community pharmacists addressing many of those regulatory and administrative barriers.
In this session, Tyler Varisco, PharmD, PhD, who led this initiative, will review the evidence around safe and effective use of buprenorphine and how to implement the PhARM-OUD Guideline’s recommendations in practice. Register here. This webinar is sponsored by the Foundation for Opioid Response Efforts.
